Resumes
Resumes
George Gereg Phones & Addresses
-
13 Maple Row, Bethel, CT 06801 (203) 748-1556
-
13 Maple Row, Bethel, CT 06801
Publications
Us Patents
Method For Predicting The Suitability Of A Substance For Dry Granulation By Roller Compaction Using Small Sample Sizes
View pageUS Patent:
6752939, Jun 22, 2004
Filed:
Jul 11, 2001
Appl. No.:
09/902086
Inventors:
George W. Gereg - Bethel CT
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc. - Ridgefield CT
International Classification:
B29B 1114
US Classification:
264 401, 264115, 264118, 264120, 264122, 264123
Abstract:
An apparatus for fabricating small compacts of formulations of a drug candidate, and a method for determining if a drug candidate, alone or in a formula mix, is suitable for dry granulation by a roller compactor based on physical measurements generated in part from such small compact.
Methods For Coating Pharmaceutical Core Tablets
View pageUS Patent:
6808721, Oct 26, 2004
Filed:
Oct 29, 2002
Appl. No.:
10/282383
Inventors:
Michael Cappola - Wilton CT
George W. Gereg - Bethel CT
Susan Way - Danbury CT
George W. Gereg - Bethel CT
Susan Way - Danbury CT
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc. - Ridgefield CT
International Classification:
A61K 928
US Classification:
424474, 424475, 424480
Abstract:
A formulation comprising, and process for preparing, improved oral dosage forms of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, a chemical entity with anti-inflammatory properties. Granulation of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea within specified ranges provides improved dissolution of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and oral bioavailability, as well as content uniformity. Incorporation into the formulation of an aqueous soluble inclusion compound capable of forming a complex with 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, such as beta-cyclodextrin provides enhanced stability of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, in particular in highly ionic environments. Chipping and disintegration of tablets containing more than about 10% betacyclodextrin can be prevented by applying a polymeric coat to the surface of the tablet at a temperature below 40Â C.
Oral Dosage Formulations Of 1-(5-Tert-Butyl-2-P-Tolyl-2H-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl] Urea
View pageUS Patent:
20020031544, Mar 14, 2002
Filed:
Jul 11, 2001
Appl. No.:
09/902822
Inventors:
Michael Cappola - Wilton CT, US
George Gereg - Bethel CT, US
Susan Way - Danbury CT, US
George Gereg - Bethel CT, US
Susan Way - Danbury CT, US
International Classification:
A61K031/5377
A61K009/48
A61K009/20
A61K009/48
A61K009/20
US Classification:
424/452000, 514/235800, 424/465000
Abstract:
A formulation comprising, and process for preparing, improved oral dosage forms of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, a chemical entity with anti-inflammatory properties. Granulation of 1-(5-tert-but l-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea within specified ranges provides improved dissolution of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and oral bioavailability, as well as content uniformity. Incorporation into the formulation of an aqueous soluble inclusion compound capable of forming a complex with 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, such as beta-cyclodextrin provides enhanced stability of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, in particular in highly ionic environments. Chipping and disintegration of tablets containing more than about 10% betacyclodextrin can be prevented by applying a polymeric coat to the surface of the tablet at a temperature below 40 C.
Batch Fluid Bed Processor
View pageUS Patent:
20030230004, Dec 18, 2003
Filed:
May 29, 2003
Appl. No.:
10/448649
Inventors:
Anne Borsavage - New Milford CT, US
Michael Cappola - Wilton CT, US
George Gereg - Bethel CT, US
Michael Cappola - Wilton CT, US
George Gereg - Bethel CT, US
Assignee:
Boehringer Ingelheim pharmaceuticals, Inc. - Ridgefield CT
International Classification:
F26B017/00
US Classification:
034/576000
Abstract:
A batch fluid bed processing machine for processing products. The batch fluid bed processing machine has a container and a gas source coupled to a first end of the container. An expansion chamber is coupled to a second end of the container. An expansion funnel having a second open end is coupled to an interface between the expansion chamber and the container. A column is mounted in the container between the expansion funnel and the gas source. A gas stream is passed from the gas source and through the container. Products may be coated or dryed in the gas stream.
Apparatus For Predicting The Suitability Of A Substance For Dry Granulation By Roller Compaction Using Small Sample Sizes
View pageUS Patent:
20040142059, Jul 22, 2004
Filed:
Jan 12, 2004
Appl. No.:
10/755531
Inventors:
George Gereg - Bethel CT, US
Assignee:
Boehringer Ingelheim - Ridgefield CT
International Classification:
B29C043/02
US Classification:
425/193000, 425/354000
Abstract:
An apparatus for fabricating small compacts of formulations of a drug candidate, and a method for determining if a drug candidate, alone or in a formula mix, is suitable for dry granulation by a roller compactor based on physical measurements generated in part from such small compact.
Class Of Surfactant-Like Materials
View pageUS Patent:
20060068007, Mar 30, 2006
Filed:
Sep 16, 2005
Appl. No.:
11/228123
Inventors:
Jinjiang Li - New Milford CT, US
Shirlynn Chen - Somers NY, US
George Gereg - Bethel CT, US
Mariotte Corson - Newtown CT, US
Shirlynn Chen - Somers NY, US
George Gereg - Bethel CT, US
Mariotte Corson - Newtown CT, US
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc. - Ridgefield CT
International Classification:
A61K 9/20
A61K 31/355
A61K 31/355
US Classification:
424464000, 514458000
Abstract:
This invention generally refers to a novel class of surfactant-like material that promotes the solubility of poorly soluble compounds.